Product Program year 2025 Source: CMS Open Payments

Sublocade

Drug Oud

NDC 12496-0300-1

Open in the dashboard

General payments

$1,622,132

18,350 payments

Research payments

$781,705

377 payments

Through program year 2025, $1,622,132 in general payments and $781,705 in research payments were reported against Sublocade (Oud).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

11 rows
Year Kind Amount Payments
2025 Research $15,577 24
2024 General $3,000 2
2024 Research $11,883 16
2023 Research $88,039 44
2022 Research $90,021 78
2021 General $251,359 5,641
2021 Research $102,732 55
2020 General $456,789 3,205
2020 Research $338,122 42
2019 General $910,983 9,502
2019 Research $135,330 118

Breakdown

Who paid General payments · program years 2019–2024
  1. Indivior Inc. $1,609,857 18,345 payments
  2. Indivior Canada Ltd $12,275 5 payments
Top recipients General payments · program year 2021
  1. Boston Medical Center Teaching hospital · MA $60,000 24% · 12 payments
  2. Laura Kehoe Addiction Medicine · Attleboro, MA $13,755 5% · 3 payments
  3. John Mariani Addiction Medicine · New York, NY $12,100 5% · 2 payments
  4. Tipu Khan Addiction Medicine · Ventura, CA $12,048 5% · 11 payments
  5. Cambridge Health Alliance Teaching hospital · MA $12,000 5% · 12 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2021.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2021
  1. Family Medicine $22,223 12% · 393 practitioners
  2. Nurse Practitioner, Family Nurse Practitioner $20,296 11% · 613 practitioners
  3. Addiction Medicine Family Medicine $19,988 11% · 78 practitioners
  4. Addiction Medicine Psychiatry & Neurology $19,938 11% · 21 practitioners
  5. Addiction Medicine Internal Medicine $19,387 11% · 49 practitioners

The top 5 of 81 specialties; each share is of general payments naming this product to practitioners with a specialty in 2021. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2021
  1. Massachusetts $89,532 36% · 71 recipients
  2. New York $22,546 9% · 312 recipients
  3. California $19,956 8% · 142 recipients
  4. Florida $16,240 6% · 271 recipients
  5. Pennsylvania $13,775 5% · 201 recipients

The top 5 of 47 states; each share is of general payments naming this product in 2021 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

14,506

Prescriptions dispensed, refills included

Drug cost

$29,377,424

Paid at the pharmacy, in all

Prescribers

699

With 11 or more claims of it

Medicare Part D drugs matched to SUBLOCADE, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Sublocade Buprenorphine Same name 699 14,506 $29,377,424

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Sabina Wong Family Practice IL 243 $499,457 None on record
Sahithi Gosala Internal Medicine PA 119 $240,388 $27
Bernard Gottschalk Internal Medicine NC 94 $193,393 $50
Jon Whitney Physician Assistant MA 91 $187,310 $71
Kathryn McKenna-Weiss Nurse Practitioner MA 82 $168,813 $57

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
18,350 general · 377 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record